Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. The treatment, administered as an injection under the skin, is now being developed with Hoffmann-La Roche in collaboration with MorphoSys.
Is Gantenerumab approved?
Global biotech giant Roche has announced that the U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationThe United States Food and Drug Administration (FDA or USFDA) is a federal agency of the Department of Health and Human Services. The FDA is led by the Commissioner of Food and Drugs, appointed by the President with the advice and consent of the Senate.https://en.wikipedia.org › Food_and_Drug_AdministrationFood and Drug Administration - Wikipedia (FDA) has awarded its candidate Alzheimer's Disease drug gantenerumab Breakthrough Therapy Designation, bringing it closer to finally getting a full FDA approval.
How does aducanumab enter the brain?
The lead drug they found was aducanumab.” According to Salloway, aducanumab enters the brain in very low concentrations and binds to the beta-amyloid plaques, then stimulating the immune system to help break up the plaques and remove them.